Abreu Advogados, law firm, advised the EXMceuticals, company listed on the Canadian Securities Exchange (CSE), in obtaining its first cannabis-based pharmaceutical research and development license, enabling it to take an important step in its operations in the European market.
Through this license, EXMceuticals establishes its pioneering position in the development of its activities and the conversion of its research work into wellness products and innovative solutions in Portugal. This license facilitates the importation, research and refinement processes of cannabinoids and byproducts in the national territory.
According with César Bessa Monteiro, jr., “This licensing process, supported by Abreu, was fundamental for the development and consolidation of this company's activity in Portugal. This license is truly innovative in our country and paves the way for the development and affirmation of a promising sector that has been very dynamic and offers great opportunities, creating many jobs and new opportunities for collaboration with other national and international companies.”
EXMceuticals is currently beginning the process of building and upgrading a refining station in Portugal that meets European norms. The company expects it to be completed, operational and fully licensed before the end of the first quarter of 2020, allowing it to export a large volume of products to the European Union and around the world.